Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

Minimal Residual Disease in Chronic Lymphocytic Leukemia: A New Goal?

In chronic lymphocytic leukemia (CLL), there is a growing interest for minimal residual disease (MRD) monitoring, due to the availability of drug combinations capable of unprecedented complete clinical responses. The standardized and most commonly applied methods to assess MRD in CLL are based on fl...

Full description

Bibliographic Details
Main Authors: Ilaria Del Giudice, Sara Raponi, Irene Della Starza, Maria Stefania De Propris, Marzia Cavalli, Lucia Anna De Novi, Luca Vincenzo Cappelli, Caterina Ilari, Luciana Cafforio, Anna Guarini, Robin Foà
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-08-01
Series:Frontiers in Oncology
Subjects:
chronic lymphocytic leukemia
minimal residual disease
flow cytometry
droplet digital PCR
next generation sequencing
ibrutinib
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.00689/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.00689/full

Similar Items